Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration.

OBJECTIVE An elevated C3 concentration has been reported in people with obesity, type 2 diabetes, hypertension, and dyslipidemia, and has been proposed to play a role in the development of atherosclerosis. We hypothesized that an elevated C3 concentration might be linked to insulin resistance and/or hyperinsulinemia, abnormalities commonly observed in association with the above conditions. RESEARCH DESIGN AND METHODS Fasting concentrations of C3 and acylation stimulating protein (ASP, C3adesarg), a cleavage product of C3 recently found to stimulate glucose uptake in vitro, were measured in 33 healthy nondiabetic Pima Indians (14 women and 19 men; age 27 +/- 1 and body fat 33 +/- 1%, means +/- SEM). Subjects were characterized for body composition dual-energy X-ray absorptiometry, insulin action (insulin-stimulated glucose disposal [M], hyperinsulinemic glucose clamp), and glucose tolerance (75-g oral glucose tolerance test). RESULTS Fasting C3 and ASP concentrations were positively correlated (r = 0.43, P < 0.05). Fasting C3 concentration was closely related to percent body fat (r = 0.77), M (r = -0.75), and fasting insulin concentration (r = 0.72) (all P < 0.0001). Fasting C3 concentrations remained significantly related to M and fasting insulin after adjusting for percent body fat (partial r = -0.53 and 0.33, both P < 0.05). In subjects with impaired glucose tolerance, fasting C3 concentrations were higher than in those with normal glucose tolerance--a difference that remained after adjustment for percent body fat and M. We found that fasting ASP concentrations were significantly related to percent body fat (r = 0.37, P < 0.05), but not to M or fasting insulin. CONCLUSIONS In Pima Indians, fasting C3 concentration is closely related to adiposity, insulin action, and fasting insulin levels and may thus be a mediator for the postulated link between obesity, insulin resistance, hyperinsulinemia, and possibly atherosclerosis.

[1]  Vu,et al.  Plasma acylation stimulating protein, adipsin and lipids in non‐obese and obese populations , 1999, European journal of clinical investigation.

[2]  R. Eckel,et al.  Levels of acylation stimulating protein in obese women before and after moderate weight loss. , 1991, International journal of obesity.

[3]  A. Fernandez-cruz,et al.  Plasma C3d Levels and Ischemic Heart Disease in Type II Diabetes , 1993, Diabetes Care.

[4]  H. Baumann,et al.  Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. , 1992, Molecular and cellular biology.

[5]  W. Ricart,et al.  Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness , 1999, Diabetologia.

[6]  H. Colten,et al.  Synthesis of complement components in liver and at extrahepatic sites , 1993 .

[7]  M. A. Crook,et al.  Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.

[8]  R. Pratley,et al.  Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. , 1999, Obesity research.

[9]  P. Puddu,et al.  Relationship between serum C3 levels and traditional risk factors for myocardial infarction. , 1998, Acta cardiologica.

[10]  B. Spiegelman,et al.  Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link , 1994, Diabetes.

[11]  G. Hansson,et al.  Immunological mechanisms in atherosclerosis , 1995, Journal of internal medicine.

[12]  C. Martignani,et al.  Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. , 2000, European heart journal.

[13]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[14]  S. Coppack,et al.  Adipose tissue as an endocrine and paracrine organ , 1998, International Journal of Obesity.

[15]  G. Hansson,et al.  Immune mechanisms in atherosclerosis. , 1989, Arteriosclerosis.

[16]  G. Reaven Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[17]  D. Raev,et al.  Additive effect of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis. , 1996, International journal of cardiology.

[18]  P. Puddu,et al.  Association of serum C3 levels with the risk of myocardial infarction. , 1995, The American journal of medicine.

[19]  K. Cianflone,et al.  Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. , 1997, Journal of lipid research.

[20]  A. Dalmasso,et al.  Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity , 1997, Clinical and experimental immunology.

[21]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[22]  B. Spiegelman,et al.  Perspectives in Diabetes Tumor Necrosis Factor a: A Key Component of the Obesity-Diabetes Link , 1994 .

[23]  K. Cianflone,et al.  Plasma acylation-stimulating protein in coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[24]  L. Peltonen,et al.  Serum complement and familial combined hyperlipidemia. , 1997, Atherosclerosis.

[25]  H. Colten,et al.  Complement biosynthesis in vitro by rat hepatoma cell strains. , 1975, Journal of immunology.

[26]  K. Cianflone,et al.  ASP stimulates glucose transport in cultured human adipocytes , 1997, International Journal of Obesity.

[27]  K. Cianflone,et al.  Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. , 1999, The American journal of physiology.

[28]  K. Cianflone,et al.  Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein. , 1990, The Journal of clinical investigation.

[29]  K. Cianflone,et al.  Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. , 1993, Metabolism: clinical and experimental.

[30]  K. Cianflone,et al.  Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. , 1997, Biochimica et biophysica acta.

[31]  S. Kado,et al.  Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus , 1999, Acta Diabetologica.

[32]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[33]  E. Ravussin,et al.  Use of dual-energy X-ray absorptiometry in obese individuals. , 1995, The American journal of clinical nutrition.

[34]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[35]  D. Salamon,et al.  Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. , 1998, Diabetes research and clinical practice.

[36]  K. Cianflone,et al.  The adipsin-acylation-stimulating protein pathway and microenvironmental metabolic regulation. , 1997, World review of nutrition and dietetics.